Intravitreal ranibizumab for age-related macular degeneration;Intravitreal ranibizumab mod aldersrelateret makuladegeneration

Ugeskrift for Laeger

Volumn 172, Issue 22, 2010, Pages

  Sørensen, Torben Lykke ^a   Kemp, Henrik ^a  

^a Sygehus Nord   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; RANIBIZUMAB;

AGED; ARTICLE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INJECTION; MIDDLE AGED; PROGNOSIS; RETINA MACULA DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MACULAR DEGENERATION; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 77953673969     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Jager RD, Mieler WF, Miller JW. Age-related macula degeneration. N Eng J Med 2008;358:2606-17.
2. Age-related Eye Disease Study Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macula degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36.
3. Khan JC, Thurlby DA, Shahid H et al. Smoking in age related macula degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovasculariazation. Br J Ophthalmol 2006;90:75-80.
4. Wong T, Chakravarthy U, Klein E et al. The natural history and prognosis of neovascular age-related macular degeneration. Ophthalmology 2008;115:116-26.
5. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macula degeneration with verteporfin: one-year results of 2 randomized trials - TAP report. Arch Ophthalmol 1999;117:1329-45.
6. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
7. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med 2006;355:1419-31.
8. Gragoudas ES, Adamis AP, Cunningham ET et al. Pegaptanib for neovascular age-related macular degeneration. N Eng J Med 2004;351:2805-16.
9. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus Verteporfin for neovascular age-related macular degeneration. N Eng J Med 2006;355:1432-44.
10. Boyer DS, Antoszyk AN, Awh CC et al. Subgroup analysis of the MARINA study of Ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:246-52.
11. Jager RD, Aillo LP, Patel SC et al. Risks of intravitreal injections: a comprehensive review. Retina 2004;24:676-98.